BlogHeader.png

SCIENTIST SPOTLIGHT: July 2019

Name: Shakia Carlos-Barr
Alcami Site: Wilmington, NC

How long have you been with Alcami?
I joined Alcami in May 2018 as an intern, before transitioning to a full-time position in December 2018. 

What is your role? 
Assistant Scientist, Formulations Development-Parenterals

What is the most rewarding part of your job? 
The most rewarding part of my job is knowing that our work gives hope for a better life to patients and their loved ones. In addition, we gain valuable on-the-job knowledge and experience to make us better scientists. This, in turn, helps us develop more innovative solutions that will save lives and lead to higher quality of life for patients worldwide.

Topics: Alcami Voices

Introduction to Quality by Design

Since Joseph Juran’s concept of Quality by Design (QbD) was first adopted by the US Food and Drug Administration (FDA), the pharmaceutical industry has been interpreting its concepts into a variety of approaches for implementation. At Alcami, our QbD approach considers evolving global regulatory guidances with a collaborative fit-for-purpose and pragmatic approach that can evolve throughout the lifecycle of the product. QbD starts from day one in modern product development, culminating in a chemistry manufacturing controls (CMC) package that maximizes every opportunity for a successful regulatory review and approval. The value of this approach is simple: design of robust processes for the consistent production of safe and effective products for our patients and long term cost savings for our partners through improved yields, reduced deviations, and efficient change management.

The QbD process for product development is intended to build quality into pharmaceuticals based on characteristics that define safety and efficacy. Critical quality attributes (CQAs) – specific physical, chemical, biological, and other properties – may impact product safety and efficacy and can be managed by identifying critical process parameters (CPPs) through the use of risk management tools and controlling them within the proven acceptable process design space.

Topics: Thought Leadership Regulatory Compliance Manufacturing Development Drug Product

Case Study: Abeona Therapeutics

Abeona Therapeutics, Inc. is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. Their late-stage candidate, EB-101, is an autologous, ex-vivo, gene-corrected cell therapy poised to enter a Phase 3 clinical trial for Recessive Dystrophic Epidermolysis Bullosa (RDEB).

Read this case study to learn how Alcami's extensive experience with small and large molecule development services, regulatory compliance, and specialty techniques helped

Topics: Resource Center Regulatory Compliance Biologics Analytical Testing Analytical Development Orphan Drugs

SCIENTIST SPOTLIGHT: June 2019

Name: Devon Dodd
Alcami Site: Wilmington, NC

How long have you been with Alcami?
I've been part of the Alcami team since November 2017.

What is your role? 
Formulation Development Scientist - Parenterals

What is the most rewarding part of your job? 
I would say it's two-fold. First, delivering new drugs to patients to improve quality of life or to save lives just never gets old. We're not a big pharmaceutical company, but we touch so many lives– and that is both exciting and humbling. Second, we partner with clients as close-knit teams to deliver the best possible products we can. I really enjoy the journey with clients, from proof of concept to market delivery. 

Topics: Alcami Voices Parenteral Manufacturing

Editorial: Enabling Technologies Advance Poorly Soluble Highly Potent APIs

Alcami recently contributed to a special feature in Pharmaceutical Technology magazine, titled "Enabling Technologies Advance Poorly Soluble Highly Potent APIs."

Excerpt from Alcami: In fact, challenges in containment can limit the technology that can be deployed for solubility enhancement, according to Adam Kujath, global senior director of manufacturing science and technology at Alcami. “Typical API approaches for solid dosage forms to improve solubility like micronization and spray drying are more difficult to outfit with appropriate containment systems. For instance, milling of solids, while not impossible to do in appropriate containment, poses a challenge since it tends to create dust in the breathing airspace for any worker. For parenteral formulations, lyophilization presents a similar challenge,” he says.

Topics: Thought Leadership HPAPI Editorials API Formulations

Regulatory Requirements for Early Phase Drug Product Development

Supporting a compound from discovery to clinical phases and potentially commercial phases requires an immense amount of time, energy, and money. Regulatory management is paramount during the drug development pipeline funnel, and recognizing Current Good Manufacturing Practices (CGMPs) is the foundation of drug safety and efficacy.

Every country has its own regulatory authority, responsible for enforcing rules and regulations and issuing guidelines for drug development, licensing, registration, manufacturing, marketing, and labeling of pharmaceutical products.[1]

Topics: Thought Leadership Regulatory Compliance Drug Product

Editorial: Designing a CMC Strategy for Accelerated Development of Biotherapeutics

Alcami recently contributed to a special feature in Drug Development and Delivery magazine titled "Designing a CMC Strategy for Accelerated Development of Biotherapeutics."

As the pipeline of biologic drugs intended to treat complex disease expands, the typical timeline for drug development seems to be shortening more frequently and with more intensity. There are many drivers to accelerate development.

Topics: Thought Leadership Regulatory Compliance Biologics Editorials Parenteral Manufacturing

Editorial: Novel Therapies Roundtable Discussion

Alcami recently contributed to a roundtable discussion in Pharma's Almanac magazine, answering the question:

"What truly novel therapies in the earliest stages of discovery and development do you believe will have a significant impact in the future?" 

The article shares insights to this question from Alcami, along with other companies in the biologics space.

Topics: Thought Leadership Biologics Editorials Development

SCIENTIST SPOTLIGHT: May 2019

Name: Colleen Caffarelli
Alcami Site: Edison, NJ

How long have you been with Alcami?
I joined Alcami six years ago.

What is your role? 
I am a regulatory compliance specialist II. 

What is the most rewarding part of your job?
As part of my job, I host client audits. I love meeting with our clients and seeing how the work we perform impacts their company and ultimately the patients that rely on the medications produced. Client audits provide an opportunity to see different perspectives and facilitate continuous improvement.

Topics: Alcami Voices

Alcami Pays Tribute to Fallen Patriots this Memorial Day

Alcami joined the nation in remembering and honoring fallen members of the U.S. Armed Forces this Memorial Day with a donation to the Purple Heart Foundation and a strong public showing of support for longtime Alcami employee and Vietnam veteran, Herman Anthony.

In a special tribute to the brave men and women who sacrificed their lives in service to our country, Anthony was invited by the Milwaukee Brewers to participate in a May 26 ceremony on the Miller Park playing field during the national anthem.

Topics: Company News Alcami in Action